<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060107</url>
  </required_header>
  <id_info>
    <org_study_id>C4C060921</org_study_id>
    <nct_id>NCT05060107</nct_id>
  </id_info>
  <brief_title>Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)</brief_title>
  <acronym>ExoOA-1</acronym>
  <official_title>A Phase I Study Aiming to Assess Safety and Efficacy of a Single Intra-articular Injection of MSC-derived Exosomes (CelliStemÂ®OA-sEV) in Patients With Moderate Knee Osteoarthritis (ExoOA-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francisco Espinoza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de los Andes, Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim to evaluate safety of exosomes (sEVs) from allogeneic mesenchymal stromal cells&#xD;
      delivered by an intra-articular injection in the knee of patients with mild to moderate&#xD;
      symptomatic osteoarthritis. The sEVs will be produced in a GMP-facility. We expect to enrolle&#xD;
      10 patients in this phase 1 trial and the follow-up will be up to 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2021</start_date>
  <completion_date type="Anticipated">October 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Ocurrence of any adverse reactions within 12 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of injection-related pain according to VAS scale (0-100mm)</measure>
    <time_frame>1 week</time_frame>
    <description>Pain measured by VAS scale after first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of injection-related sinovitis according to effusion grading scale of knee joint</measure>
    <time_frame>1 week</time_frame>
    <description>Synovitis measured by effusion grading scale (zero to 3+) after first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in VAS score after 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability reduction</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change in Womac subscale related to function (C) after 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>52 weeks</time_frame>
    <description>According to OMERACT-OARSI Criteria Index Response after 52 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Experimental group - sEVs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exosomes (sEVs)</intervention_name>
    <description>Exosomes 3-5x10e11 particles/dose</description>
    <arm_group_label>Experimental group - sEVs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic knee OA with VAS &gt;50mm&#xD;
&#xD;
          -  Knee OA Kellgren-Lawrence grade II to III&#xD;
&#xD;
          -  Chondromalacia grade I to III&#xD;
&#xD;
          -  Stable joint&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral symptomatic knee OA&#xD;
&#xD;
          -  Local infection&#xD;
&#xD;
          -  Neoplasia&#xD;
&#xD;
          -  Joint replacement&#xD;
&#xD;
          -  Recent use of local steroids&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Matas, MD</last_name>
    <phone>+56 2 26183347</phone>
    <phone_ext>3347</phone_ext>
    <email>jmatas@clinicauandes.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Espinoza, MD</last_name>
    <phone>+56 2 26183347</phone>
    <phone_ext>3347</phone_ext>
    <email>fespinoza@clinicauandes.cl</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de los Andes, Chile</investigator_affiliation>
    <investigator_full_name>Francisco Espinoza</investigator_full_name>
    <investigator_title>Medical Chieff Officer, Regenero / C4C</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

